This trial looks at the effects of a drug called LY3819469 on people with and without kidney problems. It'll assess safety, levels in the bloodstream, and how long it takes to get rid of. Trial length up to 17 weeks.
- Kidney Failure
- Healthy Subjects
3 Primary · 0 Secondary · Reporting Duration: Predose up to 85 days postdose
Awards & Highlights
3 Treatment Groups
LY3819469 (End-Stage Renal Disease)
1 of 3
1 of 3
LY3819469 (Severe Renal Impairment)
1 of 3
28 Total Participants · 3 Treatment Groups
Primary Treatment: LY3819469 (End-Stage Renal Disease) · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Age 18 - 85 · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is enrollment in this research project still open?
"Based on the clinicaltrials.gov data, this medical trial is no longer enrolling patients. It was initially posted on April 25th 2023 and its last update came a day prior to that date. Nevertheless, there are 954 other trials currently accepting participants at the moment." - Anonymous Online Contributor
Is this trial open to participants under the age of 25?
"This trial's eligibility criteria require that all participants are between 18 to 85 years old. For those below and above this range, there are 62 trials for minors and 510 studies specifically targeting seniors." - Anonymous Online Contributor
Has FDA clearance been granted for LY3819469 (Control)?
"Our safety rating for the control drug LY3819469 is 1 due to its Phase 1 status, which means there are limited data affirming both its efficacy and security." - Anonymous Online Contributor
Who meets the qualifications for enrollment in this experiment?
"This medical trial is open to patients aged 18-85 with kidney failure. Currently, 28 individuals are being sought after for enrollment." - Anonymous Online Contributor